CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma

Robert B Rebhun, Michael S Kent, S. A E B Borrofka, S. Frazier, Katherine A Skorupski, C. O. Rodriguez

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


Dogs with multicentric T-cell lymphoma are commonly treated with CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone. The purpose of this study was to evaluate the use of CHOP chemotherapy for dogs with multicentric T-cell lymphoma. Identification of prognostic factors in this specific subset of dogs was of secondary interest. Twenty-three out of 24 dogs responded to CHOP chemotherapy and these dogs remained on the protocol for a median of 146 days. No variable was associated with progression free survival (PFS) including stage, substage, hypercalcemia or radiographic evidence of a cranial mediastinal mass. The median overall survival time (OST) for all dogs was 235 days. Dogs that were thrombocytopenic at presentation experienced a significantly longer OST (323 versus 212 days, P = 0.01).

Original languageEnglish (US)
Pages (from-to)38-44
Number of pages7
JournalVeterinary and Comparative Oncology
Issue number1
StatePublished - Mar 2011


  • Canine
  • Chemotherapy
  • CHOP
  • Lymphoma
  • T cell

ASJC Scopus subject areas

  • veterinary(all)


Dive into the research topics of 'CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma'. Together they form a unique fingerprint.

Cite this